中國人壽(601628.SH)與國壽集團擬向國壽財險增資共90億元
格隆匯1月20日丨中國人壽(601628.SH)公佈,公司、中國人壽保險(集團)公司(“集團公司”)和中國人壽財產保險股份有限公司(“財產險公司”)擬於2022年3月31日前簽訂《中國人壽財產保險股份有限公司增資擴股合同》。據此,公司與集團公司擬分別向財產險公司增資人民幣36億元及人民幣54億元。
該次交易完成後,財產險公司的註冊資本將從人民幣188億元增至人民幣278億元,並繼續由公司和集團公司分別持有其40%和60%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.